Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

A systematic review of infliximab in the treatment of early rheumatoid arthritis

Authors Du Pan SM, Gabay C, Finckh A

Published 15 November 2007 Volume 2007:3(5) Pages 905—911


Sophie Martin Du Pan, Cem Gabay, Axel Finckh

Division of Rheumatology, Department of Internal Medicine, University of Geneva

Background: Several health authorities have recently revised the indication of infliximab (IFX) to include the treatment of early rheumatoid arthritis (RA). The aim of this systematic review of the literature was to appraise the efficacy, safety, and cost-effectiveness of early therapy with IFX.

Methods: We identified published clinical trials from 1966 to May 2006. We included randomized clinical trials (RCTs) in RA with disease duration of less than 3 years comparing the treatment of methotrexate-IFX (MTX-IFX) with methotrexate-placebo (MTX-placebo).

Results: A total of 8 studies met inclusion criteria. Three studies reported redundant data regarding the vdH Sharp Score. Out of the 5 remaining studies, 4 analyzed structural joint destruction (vdH Sharp Score) and demonstrated a significant reduction in radiographic damage progression in favor of the combination of MTX-IFX compared with MTX-placebo (–4.1 vdH Sharp Score units (95% CI: 3.5; 4.6). Three studies also displayed a benefit of MTX-IFX on functional outcomes of RA (HAQ score) and disease activity measures (DAS, ACR response criteria), although less markedly.

Conclusions: Although data might be skewed because of only 2 existing large studies with concordant data, results from RCTs demonstrate improved efficacy of the combination MTXIFX compared with MTX-placebo in early RA. However, many early RA patients probably do not require the addition of IFX to achieve a satisfying clinical and radiological course. So far, no evidence has established the superiority of MTX-IFX over MTX-prednisone or other combinations of traditional disease-modifying anti-rheumatic agents.

Keywords: rheumatoid arthritis, antirheumatic agents, infliximab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Relationship between cognitive insight and subjective quality of life in outpatients with schizophrenia

Kim JH, Lee S, Han AY, Kim K, Lee J

Neuropsychiatric Disease and Treatment 2015, 11:2041-2048

Published Date: 7 August 2015

Toxicity of pristine graphene in experiments in a chicken embryo model

Sawosz E, Jaworski S, Kutwin M, Hotowy A, Wierzbicki M, Grodzik M, Kurantowicz N, Strojny B, Lipińska L, Chwalibog A

International Journal of Nanomedicine 2014, 9:3913-3922

Published Date: 14 August 2014

Effects of size and surface of zinc oxide and aluminum-doped zinc oxide nanoparticles on cell viability inferred by proteomic analyses

Pan CH, Liu WT, Bien MY, Lin IC, Hsiao TC, Ma CM, Lai CH, Chen MC, Chuang KJ, Chuang HC

International Journal of Nanomedicine 2014, 9:3631-3643

Published Date: 2 August 2014

Regulation of dipeptidyl peptidase 4 production in adipocytes by glucose

Das SS, Hayashi H, Sato T, Yamada R, Hiratsuka M, Hirasawa N

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014, 7:185-194

Published Date: 24 May 2014

Unusual case of contralateral Horner's syndrome following stellate-ganglion block: a case report and review of the literature

Amhaz HH, Manders L, Chidiac EJ, Pallekonda V, Chakrabortty S

Local and Regional Anesthesia 2013, 6:31-33

Published Date: 10 October 2013

The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: implementation of a nationwide patient enrollment system

Nielsen JS, Thomsen RW, Steffensen C, Christiansen JS

Clinical Epidemiology 2012, 4:27-36

Published Date: 21 September 2012

Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery

Chen X, Huang W, Wong BC, Yin L, Wong YF, Xu M, Yang Z

International Journal of Nanomedicine 2012, 7:1139-1148

Published Date: 28 February 2012

A review of nasal polyposis

Jonathan Ray Newton, Kim Wong Ah-See

Therapeutics and Clinical Risk Management 2008, 4:507-512

Published Date: 11 April 2008

Current role of endovascular therapy in Marfan patients with previous aortic surgery

Ibrahim Akin, Stephan Kische, Tim C Rehders, Tushar Chatterjee, Henrik Schneider, et al

Vascular Health and Risk Management 2008, 4:59-66

Published Date: 8 February 2008